Article Text

Download PDFPDF

1140 Relaxin as a potential diagnostic biomarker for ovarian cancer- a prospective study
  1. F Gkrozou1,
  2. C Pappa2,
  3. O Tsonis3,
  4. E Dimitriou4 and
  5. M Paschopoulos5
  1. 1University Hospitals Birmingham NHS Foundation Trust, Obstetrics and Gynaecology, Birmingham, UK
  2. 2Oxford University Hospitals, NHS Foundation Trust , Gynaecological Oncology , Oxford, UK
  3. 3St Bartholomew’s Hospital, Barts Health NHS, Centre for Reproductive Medicine, London, UK
  4. 4National and Kapodistrian University of Athens, Medical School and Department of Mathematics , Athens, Greece
  5. 5University Hospital of Ioannina, Obstetrics and Gynaecology, Ioannina, Greece


Introduction/Background*Ovarian cancer is a leading cause of female mortality worldwide. Although novel approaches on this disease have been developed, overall survival rates remain moderate due to the lack of scientific evidence promoting screening at early stages of the disease. A number of biomarkers have been suggested as predictive for this type of cancer.In this study we aimed to understand the role of relaxin in different types of ovarian cancer and to assess its diagnostic and prognostic significance.

Methodology A total of eighty one (81) patients with diagnosed ovarian cancer, one hundred and four (104) women, with indication of benign ovarian cyst after appropriate imaging investigation and fourty four (44) healthy women, used as control, have been recruited. Blood samples were collected prospectively, just before the operation. We detected the levels of relaxin, Ca 125 and HE-4 and we calculated the Risk of Ovarian Malignancy Algorithm (ROMA). The outcomes of using relaxin, ca125, HE4 and ROMA values as biomarkers were compared in cases of ovarian cancer, healthy women and women with benign masses to identify the statistical importance of each marker.

Result(s)*In our study the levels of relaxin were significantly higher in cases of ovarian cancer, when they are compared with cases of benign ovarian cysts or in healthy population. The levels of Ca125, HE4 and the ROMA results are statistically significant increased in women with ovarian cancer, when they are compared with the cases of benign ovarian cyst or the healthy population. This result can potentially indicate the role of relaxin as tumour marker, similar to ca125. The levels of relaxin, in this study, are statistically significant increased depending on the stage of the disease. Women at FIGO I stage have lower levels of relaxin compared with the levels of relaxin at stage FIGO II, III or IV.

Conclusion*Our study underlines the potential value of relaxin as a diagnostic biomarker in cases of ovarian cancer. Although of limited data, it shows clearly, that high levels of relaxin were consistent in patients with ovarian cancer and the levels are even higher as staging is more severe.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.